98%
921
2 minutes
20
The research assessed calcium (Ca) and phosphorus (P) metabolism and microinflammation in malnourished uremic patients, focusing on the severity of vascular calcification, and examined the relationship between Ca and P metabolism indicators and microinflammation and the severity of vascular calcification. Seventy-eight patients undergoing hemodialysis treatment for ≥6 mo were collected. General information and anthropometric and blood biochemical indices were recorded, including gender, age, body mass index, mid-arm muscle circumference, albumin, intact parathyroid hormone, and Ca and P product (Ca×P). The severity of vascular calcification was graded. The correlation between the severity of vascular calcification in patients and each of the clinical indicators was analyzed. The diagnostic value of Ca and P metabolism and microinflammatory factors for vascular calcification in malnourished uremic patients was assessed. All enrolled patients were divided into a non-vascular calcification group (n=42) and a vascular calcification group (n=36) according to coronary artery calcification (CAC) scoring, and the probability of vascular calcification was 46%. The dialysis duration, Ca×P, P, hypersensitive C-reactive protein (hs-CRP), and interleukin 6 (IL-6) levels were significantly higher in the vascular calcification group than in the non-vascular calcification group. hs-CRP, IL-6, Ca×P, and P had predictive potency for vascular calcification in patients. CAC scores were correlated positively with hs-CRP, IL-6, Ca×P, and P. Malnourished uremic patients have a higher incidence of vascular calcification. hs-CRP, IL-6, Ca×P, and P are all independent risk factors for vascular calcification in uremic patients, and are positively correlated with the severity of vascular calcification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3177/jnsv.71.148 | DOI Listing |
Eur J Vasc Endovasc Surg
September 2025
School of Health and Medical Sciences, City St George's University of London, London, UK; St George's Vascular Institute, St George's Hospital, London, UK; Department of Surgery and Cancer, Imperial College London, London, UK. Electronic address:
Objective: Sex specific anatomical differences may contribute to observed disparities in outcomes and suitability for endovascular aneurysm repair (EVAR) between men and women with abdominal aortic aneurysms (AAAs). This study aimed to assess these differences using fully automated volume segmentation (FAVS) and explore implications for EVAR suitability.
Methods: This was a retrospective, multicentre cohort study of patients undergoing elective AAA repair between 2013 and 2023 in three UK tertiary centres.
Vascul Pharmacol
September 2025
Department of Orthopaedic Surgery, Orthopaedic Hospital Research Center, UCLA, Los Angeles, CA 90095, USA; Center for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. Electronic address:
The walls of all embryonic, foetal, and adult blood vessels contain mesodermal progenitors, distributed as pericytes in capillaries and micro vessels, and fibroblastic cells in the tunica adventitia of larger veins and arteries. Following dissociation, selection by flow cytometry, and culture, those perivascular cells turn into bona fide mesenchymal stem cells of which they possess all attributes. In vivo, the adventitial cellular niche supports several spatially-organized subsets of mesodermal progenitors biased toward either osteo-, adipo-, or fibrogenesis, and dominated by more primitive, multi-lineage stem-like cells.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
August 2025
Northwestern University, Chicago, IL, United States.
Front Bioeng Biotechnol
August 2025
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Background: Isowighteone, an isoflavonoid compound derived from L.f. (, Moraceae), has demonstrated significant anti-inflammatory properties in prior studies.
View Article and Find Full Text PDFAm J Physiol Cell Physiol
September 2025
Obesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM). However, robust clinical evidence has demonstrated that their therapeutic benefits extend beyond glycemic control. SGLT2i reduce hospitalization for heart failure (HF), slow the progression of chronic kidney disease (CKD), and provide cardiorenal protection even in individuals without diabetes but with cardiovascular disease.
View Article and Find Full Text PDF